Early in vivo expressed antigens and their role in virulence, immune response, and vaccines for coccidioidomycosis

早期体内表达的抗原及其在球孢子菌病毒力、免疫反应和疫苗中的作用

基本信息

批准号：
10356626
负责人：
Paul Stephen Keim
金额：
$ 26.49万
依托单位：
NORTHERN ARIZONA UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-24 至 2027-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10356626
关键词：
Accounting Animal Model Antigens Area Arizona Award Budgets Businesses Clinical Clinical Research Clinical Trials Coccidioidomycosis Collaborations Communication Communities Data Development Diagnostic Ensure Evaluation Faculty Familiarity Feedback Fostering Funding Goals Human Resources Immune response Individual Institution Joints Knowledge Lead Leadership Length Life Location Medical center Mentors Monitor National Institute of Allergy and Infectious Disease Performance Pilot Projects Postdoctoral Fellow Primates Publications Reporting Research Research Institute Research Project Grants Resources Role Schedule Scheme Series Services Structure Students Time TimeLine Training Travel United States National Institutes of Health Universities Vaccines Videoconferencing Virulence Washington Work collaborative environment desert fever early-career faculty experience in vivo innovation meetings member novel vaccines outreach programs research and development student mentoring success synergism translational genomics virtual working group

项目摘要

Administrative Core Section SUMMARY The Virulence, Immune Response, and Vaccine (VIRV) Cocci Cooperative Research Center (CCRC) will be directed by the administrative core (AdC) and a senior management team (SMT). The SMT is composed of Drs. Paul Keim (overall PI/PD), Bridget Barker, Deborah Fuller, and Erik Settles – all experienced scientific project managers. This is an aggregate effort by Northern Arizona University, University of Washington, the University of Arizona, the Kern Medical Center, the Tulane National Primate Research Center, and the Translational Genomics Research Institute that will capitalize upon the strengths of each institution and will synergistically foster a collaborative and productive scientific culture. Because it is a multi-Institutional program, coordination and communication are essential and will be an emphasis in the AdC. All of the individual Cores and Research Projects (RPs) will be represented on the SMT, which will provide effective vertical and horizontal communication, and management. Weekly meetings will be held within each of the CCRC components in addition to regular monthly cross-CCRC sessions to foster engagement and collaboration across the projects. All meetings will be supported by video conferencing and recorded, to lower participation barriers across the physical research locations. Slack accounts and channels will be an important part of the management communication scheme. Financial and compliance monitoring, along with reporting activities of the Cores and RPs, will be managed by the AdC, which includes a project manager with business accounting support. Major services, such as publication, animal models, and travel will be funded through the Cores to support the three individual RPs. Milestones and Timelines will be generated for each component and reviewed monthly during the SMT meetings. Outreach activities will be assessed and are part of the success metrics. Integral to these CCRC coordination efforts will be our program in Development Research Projects (DRPs) that will foster early career faculty, cross CCRC participation, and innovative ideas. The AdC will solicit, evaluate, award, and monitor the DRPs throughout the life of the VIRV-CCRC. Outreach will include our virtual seminar program and online forums to support the Valley Fever clinical and research communities, particular to other NIAID CCRC’s. Professional development, training, and mentoring of students, postdoctoral fellows, and junior faculty will be encouraged and supported by the AdC. Scientific working groups within and across the NIAID Cocci Centers will be fostered with the seminar series, travel funds, and joint pilot projects. The VIRV-CCRC team members will be expected to collaborate extensively and to produce relevant and impactful scientific products, including potentially a novel vaccine ready for clinical trials.

行政核心部分概括毒力、免疫反应和疫苗 (VIRV) 球菌合作研究中心 (CCRC) 将由行政核心（AdC）和高级管理团队（SMT）领导。SMT由以下人员组成。 Paul Keim 博士（整体 PI/PD）、Bridget Barker、Deborah Fuller 和 Erik Settles——都是经验丰富的科学家这是北亚利桑那大学、华盛顿大学、项目经理的共同努力。亚利桑那大学、克恩医学中心、杜兰国家灵长类动物研究中心和转化基因组学研究所将利用每个机构的优势，并将协同培育协作和富有成效的科学文化，因为它是一个多机构的文化。计划、协调和沟通至关重要，并将成为 AdC 的重点。各个核心和研究项目 (RP) 将出现在 SMT 上，这将提供有效的每周将在每个部门内召开纵向和横向沟通和管理会议。除了每月定期举行的跨 CCRC 会议之外，CCRC 还举办了旨在促进参与和参与的活动跨项目的协作将由视频会议支持并进行录制，以 Slack 帐户和渠道的参与门槛将降低。财务和合规监控以及管理沟通计划的重要组成部分。核心和 RP 的报告活动将由 AdC 管理，其中包括一名项目经理并提供商业会计支持。将通过核心提供资金来支持三个单独的里程碑和时间表。每个组成部分都将在 SMT 会议期间每月进行评估。这些 CCRC 协调工作的一部分将是我们的计划。发展研究项目 (DRP) 将培养早期职业教师、交叉 CCRC 参与以及 AdC 将在整个生命周期内征求、评估、奖励和监控 DRP。 VIRV-CCRC 外展活动将包括我们的虚拟研讨会计划和在线论坛，以支持硅谷。发烧临床和研究社区，特别是其他 NIAID CCRC 专业发展，将鼓励和指导学生、博士后研究员和初级教师将在 NIAID 球菌中心内部和跨中心建立科学工作组。 VIRV-CCRC 团队成员将参加系列研讨会、旅行基金和联合试点项目。预计主要合作并生产相关且有影响力的科学产品，包括可能是一种准备进行临床试验的新型疫苗。